Table 1.

Patient characteristics by anemia status during treatment and follow-up

N = 424Hb ≥12 g/dL
Hb <12 g/dL
χ2P
n = 347 (81.8%)n = 77 (18.2%)
Age
    <35 y26 (6.1%)80.8%19.2%0.0210.884
    ≥35 y398 (93.9%)81.9%18.1%
Tumor stage
    T1239 (56.4%)84.1%15.9%3.2170.200
    T2167 (39.4%)77.8%22.2%
    T318 (4.2%)88.9%11.1%
Axillary lymph nodes
    Negative204 (48.1%)82.4%17.6%0.1050.991
    Positive (1-3 nodes)150 (35.4%)81.3%18.7%
    Positive (4-10 nodes)58 (13.7%)81.0%19.0%
    Positive (>10 nodes)12 (2.8%)83.3%16.7%
Histologic grading
    G1, G2, or unknown308 (72.6%)79.7%20.3%3.2660.071
    G3116 (27.4%)87.3%12.7%
Estrogen receptor status
    Negative25 (5.9%)88.0%12.0%0.8670.648
    Positive294 (69.3%)81.0%19.0%
    Strongly positive105 (24.8%)82.9%17.1%
Progesterone receptor status
    Negative53 (12.5%)81.1%18.9%0.5160.773
    Positive230 (54.2%)83.0%17.0%
    Strongly positive141 (33.3%)80.1%19.9%
Type of surgery
    Breast-conserving surgery270 (63.7%)86.3%13.7%9.9340.002*
    Modified radical mastectomy154 (36.3%)74.0%26.0%
Radiotherapy
    No127 (30.0%)72.4%27.6%10.7760.001*
    Yes297 (70.0%)85.9%14.1%
  • * Statistically significant.